Dancing in the Dark: Discovery, Validation, & Clinical Application of Dark Antigens®
- Unlocking a new target class: The “Dark Genome” is a rich, untapped source of tumour-specific antigens, overcoming the limitations of many conventional TCE targets (poor tumour specificity, low prevalence, low intra-tumoural homogeneity)
- End-to-end platform solution: Enara Bio has built integrated discovery (EDAPT) and engineering (EnTiCE) platforms to identify Dark Antigens® and generate optimised TCEs capable of effective engagement at physiological antigen levels
- First-in-class validation with DARKFOX/ENA101: We have identified a highly tumour-specific, broadly expressed antigen and targeted it with a potent, selective TCE showing strong preclinical efficacy, safety, and translational potential